? ? The program described in this grant application will train post-doctoral fellows for a career in academic hematopoietic cell transplantation. Candidates with either an M.D. or M.D./Ph.D. degrees who have completed training in internal medicine and either hematology or oncology will be considered for the two to three year training program. The first year of the training program includes an intensive experience in clinical hematopoietic cell transplantation. During this initial phase, trainees will be exposed to the full spectrum of hematopoietic cell transplantation including autologous and allogeneic transplantation from related and unrelated donors. The trainees' experience will be centered on the Blood and Marrow Transplant Unit, E1, at Stanford University Hospital. In addition, outpatient experience in the Clinical Cancer Center Infusion Treatment Area and clinics will be provided. The trainees will also rotate through the Blood and Marrow Transplantation Area and Cellular Processing laboratory and HLA laboratories for one month each. Following completion of the clinical rotations, trainees will spend approximately one to two and one-half years of in-depth study with a member of the faculty. These faculty members are individuals whose research focuses on the basic science and clinical application of hematopoietic cell transplantation. Intensive laboratory experience will prepare the trainee for a career in academic hematopoietic cell transplantation. In addition, the trainees will be responsible for the conduct of a clinical protocol trial which is either on-going or developed in consultation with a member of the Bone Marrow Transplantation Division faculty. At the conclusion of their training, individuals will be prepared for a career as an independent investigator well studied in the basic and clinical areas of hematopoietic cell transplantation. (End of Abstract) ? ? ?

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-J (F1))
Program Officer
Chang, Henry
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Msaouel, Pavlos; Lam, Anthony P; Gundabolu, Krishna et al. (2014) Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica 99:930-6
Meyer, Everett H; Hsu, Andro R; Liliental, Joanna et al. (2013) A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. Blood 121:4955-62
Dunleavy, Kieron; Pittaluga, Stefania; Maeda, Lauren S et al. (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408-16
Lam, Anthony P; Gundabolu, Krishna; Sridharan, Ashwin et al. (2013) Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia. Am J Hematol 88:E245-9
Gill, Saar; Vasey, Adrianne E; De Souza, Alysha et al. (2012) Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 119:5758-68
Logan, Aaron C; Weissman, Irving L; Shizuru, Judith A (2012) The road to purified hematopoietic stem cell transplants is paved with antibodies. Curr Opin Immunol 24:640-8
Warsch, Sean; Hosein, Peter J; Maeda, Lauren S et al. (2012) A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. Leuk Lymphoma 53:1299-1305
Herges, Katja; de Jong, Brigit A; Kolkowitz, Ilan et al. (2012) Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler 18:398-408
Maeda, Lauren S; Lee, Mark; Advani, Ranjana H (2011) Current concepts and controversies in the management of early stage Hodgkin lymphoma. Leuk Lymphoma 52:962-71
Chen, George L; Arai, Sally; Flowers, Mary E D et al. (2011) A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood 118:4070-8

Showing the most recent 10 out of 17 publications